Inclusion Criteria

Concurrent Medication:

Allowed:

• Acetaminophen under the supervision of a study physician.

Prior Medication:

Required for at least 6 weeks prior to study entry:

• Zidovudine at a dose of at least 300 mg/day.
• Allowed:
• Aerosolized pentamidine prior to combination therapy.

Patients must demonstrate the following clinical and laboratory findings:

• Currently receiving zidovudine (AZT) at a dose of at least 300 mg/day and have received the drug for at least 6 weeks.
• Have a life expectancy of = or > 4 months.
• Available for the duration of the study and for follow-up visits.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions will be excluded:

• Evidence of active life-threatening opportunistic infection with bacterial, viral, fungal, or protozoan pathogens during the 6-week period prior to and during the 5-day period of combination therapy.
• A fever > 101 degrees F within the past 10 days.
• Significant central nervous system disease, including acquired immunodeficiency syndrome (AIDS), dementia, psychiatric disabilities, or seizure disorders.
• Significant cardiac (New York Heart Association stage III or IV) and/or pulmonary disease (forced expiratory volume < 75 percent).
• Kaposi's sarcoma or other AIDS related malignancy.
• Evidence of malabsorption as indicated by 10 percent weight loss within the last 3 months.

Concurrent Medication:

Excluded:

• Cardiac medications.
• Glucocorticosteroids.
• Probenecid.
• Acetylsalicylic acid.
• Trimethoprim / sulfamethoxazole.
• Acyclovir.
• Allopurinol.
• Drugs causing anemia, neutropenia, or nephrotoxicity.
• Aerosolized pentamidine during combination therapy.
• Nonsteroidal anti-inflammatory drugs by patients with thrombocytopenia (<75000 platelets/mm3).
• Acetaminophen except under supervision of a study physician.

Patients with the following conditions will be excluded:

• Evidence of active life-threatening opportunistic infection with bacterial, viral, fungal, or protozoan pathogens during the 6-week period prior to and during the 5-day period of combination therapy.
• A fever > 101 degrees F within the past 10 days.
• Significant central nervous system disease, including acquired immunodeficiency syndrome (AIDS), dementia, psychiatric disabilities, or seizure disorders.
• Significant cardiac (New York Heart Association stage III or IV) and/or pulmonary disease (forced expiratory volume < 75 percent).
• Kaposi's sarcoma or other AIDS related malignancy.
• Evidence of malabsorption as indicated by 10 percent weight loss within the last 3 months.

Prior Medication:

Excluded within 4 weeks of study entry:

• Any antiretroviral drug, except zidovudine (AZT).
• Excluded within 12 weeks of study entry:
• Immunotherapy, including interleukins, interferons, tumor necrosis factor.
• Other cytokines.
• Biologic response modifiers.
• Monoclonal antibodies.
• BCG vaccines.

Active drug or alcohol abuse.